Oppenheimer Sticks to Its Buy Rating for Kura Oncology (KURA)

Oppenheimer analyst Jay Olson maintained a Buy rating on Kura Oncology (KURAResearch Report) yesterday and set a price target of $28. The company’s shares closed on Friday at $15.85.

Olson noted:

“KURA reported clinical activity of tipifarnib in a retrospective subset analysis of pancreatic cancer patients associated with high CXCL12 (data from JNJ’s trial INT-11). Tipifarnib has shown clinical activity in a similar analysis in HRAS mutant HNSCC, PTCL and AITL. The CXCL12/CXCR4 pathway mediates tumor cell homing and tolerogenesis of the immune system and tipifarnib inhibits this pathway. Low KRAS mutant allele frequency (<5%) could help identify subjects with tumors overexpressing CXCL12 as well as sites of metastasis formation (lymph nodes and liver have high CXCL12 vs. lung has low expression). Tipifarnib showed an OS benefit in patients with nodal and liver metastasis and absence of abdominal pain (suspected high CXCL12 expression) and not in patients with lung metastasis (low CXCL12)."

According to TipRanks.com, Olson is currently ranked with no stars on a 0-5 star ranking scale, with an average return of -8.2% and a 37.9% success rate. Olson covers the Healthcare sector, focusing on stocks such as Madrigal Pharmaceuticals Inc, Conatus Pharmaceuticals, and Enanta Pharmaceuticals.

The word on The Street in general, suggests a Strong Buy analyst consensus rating for Kura Oncology with a $31.50 average price target.

See today’s analyst top recommended stocks >>

The company has a one-year high of $24.03 and a one-year low of $10.20. Currently, Kura Oncology has an average volume of 297.8K.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Kura Oncology, Inc. operates as a clinical-stage biopharmaceutical company which engages in the research and development of medicines for the treatment of cancer. Its pipeline includes Tipifarnib which is a Farnesyl transferase inhibitor for HRAS Mutant Solid Tumors, Chronic Myelomonocytic Leukemia; KO-947 which is an ERK inhibitor for MAPK Pathway Tumors; and KO-539 which is a Menin MLL inhibitor for acute leukemias. The company was founded by Troy E. Wilson, Yi Liu, Pingda Ren and Antonio Gualberto on August 22, 2014 and is headquartered in La Jolla, CA.

Leave a Reply

Your email address will not be published. Required fields are marked *